TCR2 Therapeutics, an early-stage biotech developing T cell immunotherapies for various cancers, announced terms for its IPO on Friday.
The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, TCR2 Therapeutics would command a fully diluted market value of $374 million.
TCR2 Therapeutics was founded in 2015 and plans to list on the Nasdaq under the symbol TCRR. Jefferies, SVB Leerink and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of February 11, 2019.
